Clinical Trial Update: Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia [Phase 2]

View source ↗

Summary

A Phase II study of DA-3031 (PEG-G-CSF) for chemotherapy-induced neutropenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia

Drugs mentioned

• DA-3031 (PEG-G-CSF) (pegylated granulocyte colony-stimulating factor)

Snippet

Sponsor: Dong-A ST Co., Ltd. | Conditions: Chemotherapy Induced Neutropenia | Phase 2 | Status: COMPLETED